Thyroid cancer
We activate antitumor immunity in thyroid cancer — gently and without severe toxic burden.
About the disease
Thyroid cancer responds well to surgical and radioiodine therapy, but in aggressive and recurrent forms, it is crucial to connect the resources of your own immune system.
Active immunotherapy forms a specific antitumor response and complements standard methods, reducing the risk of relapse.
Standard addition
Enhances the outcome of surgery and radioiodine therapy.
No intoxication
Gentle impact on healthy tissues.
Relapse prevention
Immune surveillance destroys residual cells.
Extracorporeal immunotherapy
We move the immune 'training' process outside the body (ex vivo) — to an environment where we can create the conditions for training immunocompetent cells without creating any risk to your body.
Procedure
We draw your venous blood (up to 90 ml).
Activation (18 hours)
In the laboratory, using our proprietary technology (patents in Russia, the US, and the EU), we incubate the cells with immunomodulatory drugs and xenogeneic antigens. The cells receive a precise target.
Strike
We return the trained cells via subcutaneous injections. A powerful, multi-component immune response is developed.
Consolidation
The maintenance course forms long-term immunological memory, protecting against relapses for years.
Other directions
Kidney cancer
Specific immune response against renal cell carcinoma without severe toxic burden.
Lung cancer
Comprehensive impact on the tumor while preserving healthy tissues across various forms of lung cancer.
Breast cancer
Forming long-term antitumor defense, reducing the risks of relapses and metastasis.
Discuss your situation
Leave your contact details. Our medical coordinator will contact you shortly to answer any questions.